Revival of Chinese Biotechs: Late-stage Assets Attract Investors
TLDR: Chinese biotechs are seeing an influx of cash, particularly in late-stage assets, as investors, including state-owned venture capitals, show interest in the market. The Bio China International Convention in Suzhou highlighted